Natural Plant Extraction Player, Chongqing Joywin Natural Products Co., Ltd. plans to go public in the US via a merge with a special purpose acquisition company (SPAC)with estimated valuation of $300 million
July 05, 2023 20:22 ET
|
Chongqing Joywin Natural Products Co., Ltd.
Chongqing, China, July 05, 2023 (GLOBE NEWSWIRE) -- Chongqing Joywin Natural Products Co., Ltd. (hereinafter referred to as Chongqing Joywin) is a company that focuses on extracting various natural...
InveniAI to Participate in the Truist Securities Life Sciences AI Symposium – Biotech & Tools
February 24, 2022 12:39 ET
|
InveniAI LLC
GUILFORD, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development,...
Pan-Biome Pharmaceuticals, Inc. provides update on its longevity research program: its compounds modulate inflammation, the gut microbiome, and increase lifespan of C. elegans by 30%
December 02, 2021 10:00 ET
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc., a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...
Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole
September 16, 2021 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...
Derm-Biome Pharmaceuticals, Inc. files a US provisional patent for a new generation of natural product-based derivatives and their uses for treating chronic inflammatory skin conditions
June 29, 2021 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
June 10, 2021 16:30 ET
|
aTyr Pharma, Inc.
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are...
InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
May 11, 2021 08:10 ET
|
InveniAI LLC
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
October 06, 2020 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
Intravenous Immunoglobulin (IVIG) Market To Reach USD 15.67 Billion By 2026 | Reports And Data
May 28, 2019 12:38 ET
|
Reports And Data
The rapid increase in neurological disorders, increase in geriatric population, and continuous increase in the number of patients are fueling the market growth. Market Size – USD 9.43 Billion in...
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
May 22, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing — — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE...